CliffBio
small molecule

CYCLOSPORINE

CYCLOSPORINE

Loss of exclusivity—loss of exclusivity
CompanySAPTALIS PHARMACEUTICALS LLC

Drug detail

Brand nameCYCLOSPORINE
Active ingredientCYCLOSPORINE
Strength0.05%
Dosage formEMULSION
RouteOPHTHALMIC
ModalitySmall molecule
FDA approvalJuly 2024
Marketing statusRX

More from SAPTALIS PHARMACEUTICALS LLC

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

CYCLOSPORINE patent cliff — loss of exclusivity — | CliffBio